Elanco Animal Health Incorporated (ELAN) — closed signal from September 24, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 23, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published September 24, 2025
Elanco's near-term story is driven by fresh news. Being added to the S&P MidCap 400 can trigger automatic buying from investment funds, and the FDA removed a vaccine risk warning from Zenrelia, easing concern around a key product. The stock has fallen but is starting to stabilize. Over the next 0-3 months we expect a rebound from these forces, but we would stay disciplined if momentum fades. This is a short-term view while fundamentals improve.
Primary drivers
- Joining the S&P MidCap 400 can spark automatic fund buying demand
- FDA removed a warning on Zenrelia, easing safety worries for this key product
- Shares fell hard but are starting to stabilize and recover in recent trading
- Business results trail the stock move, so this stays a short-term idea
How it played out
ELAN: target was not reached after a 24.2% peak
Lyra published ELAN at 19.08 on 2025-09-24 as a short-term rebound idea. The thesis expected 25% growth over 0-3 months. It pointed to S&P MidCap 400 inclusion, the FDA removing a Zenrelia vaccine risk warning, recent stabilization after a hard fall, and still-lagging business results.
Inside the window, ELAN rose to 23.7 on 2025-11-26, a 24.2% peak gain. The target was 23.84, so it stayed below the target. It never got there. By 2025-12-23, the stock ended at 22.22. The thesis mostly played out on direction and size, but it missed the published target.
What happened during the window
On 2025-12-09, Investor's Business Daily reported that Elanco had reiterated its fourth-quarter and 2025 guidance at its investor day. The same report said third-quarter revenue rose 10%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.